Angiotensin Receptor Regulation By Upstream Short Open Reading Frames

上游短开放阅读框对血管紧张素受体的调节

基本信息

  • 批准号:
    8894076
  • 负责人:
  • 金额:
    $ 72.69万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2014
  • 资助国家:
    美国
  • 起止时间:
    2014-07-17 至 2018-05-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Angiotensin II (Ang II) plays a key role in fluid homeostasis and blood pressure (BP). We have recently found that a seven amino acid peptide (PEP7) encoded within a short open reading frame in exon 2 of the 5' leader sequence of the angiotensin type 1a receptor (AT1aR) mRNA inhibits Ang II activation of extracellular signal-regulated protein kinases 1 and 2 (Erk1/2) and regulates AT1aR trafficking in cells. PEP7 also markedly reduced Ang II-mediated sodium intake without having any effect on Ang II-mediated water intake and it antagonized Ang II- induced increases in BP. Aim 1 will determine the signaling mechanism by which PEP7 inhibits Erk1/2 activation. We will test the hypothesis that PEP7 inhibition of Erk1/2 activation is Ang II dependent and mediated via the AT1aR-G protein-independent ß-arrestin signaling pathway. We will also investigate PEP7 regulation of AT1aR vesicular trafficking by inhibiting AT1aR coupling to the ß-arrestin pathway using both pharmacological and molecular approaches, and confocal microscopy. Aim 2 will elucidate the mechanism by which PEP7 regulates fluid and electrolyte homeostasis. We will investigate PEP7 effects in vivo in pathophysiological models of elevated sodium intake including hyponatremic hypovolemia and isotonic hypovolemia as well as conditions that modulate central oxytocin and vasopressin pathways and those that selectively inhibit G protein-mediated protein kinase C and G protein-independent Erk1/2 signaling cascades. Aim 3 will determine if the antihypertensive effects of PEP7 are Ang II-dependent by investigating PEP7 effects on arterial pressure in models of Ang II- and catecholamine- dependent hypertension. We will also determine if PEP7 is effective at lowering BP in two models of salt-sensitivity and what role reduced sodium intake plays in these effects. By achieving these aims, we will gain insight into PEP7 biology that could be leveraged toward developing novel interventions for diseases that are worsened by dietary sodium, like salt- sensitive hypertension.
描述(由申请人提供):血管紧张素II(Ang II)在体液稳态和血压(BP)中起关键作用。我们最近发现,在血管紧张素1a型受体(AT 1aR)mRNA的5'前导序列的外显子2的短开放阅读框内编码的7个氨基酸的肽(PEP 7)抑制细胞外信号调节蛋白激酶1和2(Erk 1/2)的Ang II活化,并调节AT 1aR在细胞中的运输。PEP 7还显著降低了Ang II介导的钠摄入量,而对Ang II介导的水摄入量没有任何影响,并且它拮抗了Ang II诱导的BP升高。目的1将确定PEP 7抑制Erk 1/2激活的信号转导机制。我们将检验PEP 7抑制Erk 1/2激活是Ang II依赖性的,并通过AT 1aR-G蛋白非依赖性的β-arrestin信号通路介导的假设。我们还将研究PEP 7调节AT 1aR囊泡运输抑制AT 1aR偶联到β-arrestin途径使用药理学和分子方法,共聚焦显微镜。目的2将阐明PEP 7调节体液和电解质稳态的机制。我们将在钠摄入量升高的病理生理模型中研究PEP 7的体内作用,包括低钠性低血容量和等渗性低血容量以及调节中枢催产素和加压素途径的条件以及选择性抑制G蛋白介导的蛋白激酶C和G蛋白的条件。非依赖性Erk 1/2信号级联反应。目的3将通过研究PEP 7在Ang II和儿茶酚胺依赖性高血压模型中对动脉压的影响来确定PEP 7的抗高血压作用是否是Ang II依赖性的。我们还将确定PEP 7在两种盐敏感性模型中是否有效降低血压,以及减少钠摄入在这些效应中起什么作用。通过实现这些目标,我们将深入了解PEP 7生物学,可以利用它来开发新的干预措施,用于因膳食钠而恶化的疾病,如盐敏感性高血压。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Willis K. Samson其他文献

Cardiovascular Hormones
心血管激素
  • DOI:
  • 发表时间:
    2007
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Willis K. Samson;Meghan M. Taylor
  • 通讯作者:
    Meghan M. Taylor
Chapter 203 – Prolactin
第203章-催乳素
  • DOI:
  • 发表时间:
    2013
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Willis K. Samson
  • 通讯作者:
    Willis K. Samson
Atrial natriuretic factor and the central nervous system.
心房钠尿因子和中枢神经系统。
The effect of fever on central α-MSH concentrations in the rabbit
发热对家兔中枢α-MSH浓度的影响
  • DOI:
  • 发表时间:
    1981
  • 期刊:
  • 影响因子:
    3
  • 作者:
    Willis K. Samson;J. M. Lipton;J. Zimmer;J. Glyn
  • 通讯作者:
    J. Glyn
Pituitary site of action of endothelin: selective inhibition of prolactin release in vitro.
内皮素的垂体作用位点:体外选择性抑制催乳素释放。

Willis K. Samson的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Willis K. Samson', 18)}}的其他基金

Angiotensin Receptor Regulation By Upstream Short Open Reading Frames
上游短开放阅读框对血管紧张素受体的调节
  • 批准号:
    9005356
  • 财政年份:
    2014
  • 资助金额:
    $ 72.69万
  • 项目类别:
Angiotensin receptor regulation by upstream short open reading frames
上游短开放阅读框对血管紧张素受体的调节
  • 批准号:
    8773952
  • 财政年份:
    2014
  • 资助金额:
    $ 72.69万
  • 项目类别:
Orexinergic Pathways in Central Autonomic Control
中枢自主控制中的食欲素能通路
  • 批准号:
    6654925
  • 财政年份:
    2002
  • 资助金额:
    $ 72.69万
  • 项目类别:
Orexinergic Pathways in Central Autonomic Control
中枢自主控制中的食欲素能通路
  • 批准号:
    6798202
  • 财政年份:
    2002
  • 资助金额:
    $ 72.69万
  • 项目类别:
Orexinergic Pathways in Central Autonomic Control
中枢自主控制中的食欲素能通路
  • 批准号:
    6938576
  • 财政年份:
    2002
  • 资助金额:
    $ 72.69万
  • 项目类别:
Orexinergic Pathways in Central Autonomic Control
中枢自主控制中的食欲素能通路
  • 批准号:
    6544728
  • 财政年份:
    2002
  • 资助金额:
    $ 72.69万
  • 项目类别:
Physiology of the Prolactin Releasing Peptides
催乳素释放肽的生理学
  • 批准号:
    7789408
  • 财政年份:
    2001
  • 资助金额:
    $ 72.69万
  • 项目类别:
PHYSIOLOGY OF THE PROLACTIN RELEASING PEPTIDES
催乳素释放肽的生理学
  • 批准号:
    6638706
  • 财政年份:
    2001
  • 资助金额:
    $ 72.69万
  • 项目类别:
Physiology of the Prolactin Releasing Peptides
催乳素释放肽的生理学
  • 批准号:
    7583992
  • 财政年份:
    2001
  • 资助金额:
    $ 72.69万
  • 项目类别:
Physiology of the Prolactin Releasing Peptides
催乳素释放肽的生理学
  • 批准号:
    7395023
  • 财政年份:
    2001
  • 资助金额:
    $ 72.69万
  • 项目类别:

相似海外基金

Planar culture of gastrointestinal stem cells for screening pharmaceuticals for adverse event risk
胃肠道干细胞平面培养用于筛选药物不良事件风险
  • 批准号:
    10707830
  • 财政年份:
    2023
  • 资助金额:
    $ 72.69万
  • 项目类别:
Hospital characteristics and Adverse event Rate Measurements (HARM) Evaluated over 21 years.
医院特征和不良事件发生率测量 (HARM) 经过 21 年的评估。
  • 批准号:
    479728
  • 财政年份:
    2023
  • 资助金额:
    $ 72.69万
  • 项目类别:
    Operating Grants
Analysis of ECOG-ACRIN adverse event data to optimize strategies for the longitudinal assessment of tolerability in the context of evolving cancer treatment paradigms (EVOLV)
分析 ECOG-ACRIN 不良事件数据,以优化在不断发展的癌症治疗范式 (EVOLV) 背景下纵向耐受性评估的策略
  • 批准号:
    10884567
  • 财政年份:
    2023
  • 资助金额:
    $ 72.69万
  • 项目类别:
AE2Vec: Medical concept embedding and time-series analysis for automated adverse event detection
AE2Vec:用于自动不良事件检测的医学概念嵌入和时间序列分析
  • 批准号:
    10751964
  • 财政年份:
    2023
  • 资助金额:
    $ 72.69万
  • 项目类别:
Understanding the real-world adverse event risks of novel biosimilar drugs
了解新型生物仿制药的现实不良事件风险
  • 批准号:
    486321
  • 财政年份:
    2022
  • 资助金额:
    $ 72.69万
  • 项目类别:
    Studentship Programs
Pediatric Adverse Event Risk Reduction for High Risk Medications in Children and Adolescents: Improving Pediatric Patient Safety in Dental Practices
降低儿童和青少年高风险药物的儿科不良事件风险:提高牙科诊所中儿科患者的安全
  • 批准号:
    10676786
  • 财政年份:
    2022
  • 资助金额:
    $ 72.69万
  • 项目类别:
Pediatric Adverse Event Risk Reduction for High Risk Medications in Children and Adolescents: Improving Pediatric Patient Safety in Dental Practices
降低儿童和青少年高风险药物的儿科不良事件风险:提高牙科诊所中儿科患者的安全
  • 批准号:
    10440970
  • 财政年份:
    2022
  • 资助金额:
    $ 72.69万
  • 项目类别:
Improving Adverse Event Reporting on Cooperative Oncology Group Trials
改进肿瘤学合作组试验的不良事件报告
  • 批准号:
    10642998
  • 财政年份:
    2022
  • 资助金额:
    $ 72.69万
  • 项目类别:
Planar culture of gastrointestinal stem cells for screening pharmaceuticals for adverse event risk
胃肠道干细胞平面培养用于筛选药物不良事件风险
  • 批准号:
    10482465
  • 财政年份:
    2022
  • 资助金额:
    $ 72.69万
  • 项目类别:
Expanding and Scaling Two-way Texting to Reduce Unnecessary Follow-Up and Improve Adverse Event Identification Among Voluntary Medical Male Circumcision Clients in the Republic of South Africa
扩大和扩大双向短信,以减少南非共和国自愿医疗男性包皮环切术客户中不必要的后续行动并改善不良事件识别
  • 批准号:
    10191053
  • 财政年份:
    2020
  • 资助金额:
    $ 72.69万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了